Azithromycin-Induced Proarrhythmia and Cardiovascular Death
- 22 October 2013
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 47 (11), 1547-1551
- https://doi.org/10.1177/1060028013504905
Abstract
Objective: To review the possible association between azithromycin and increased cardiovascular risk. Data sources: A literature search of MEDLINE (1946-August 2013) was performed using the search terms macrolide, azithromycin, QT prolongation, cardiovascular, and torsade de pointes. Additional references were identified from a review of literature citations. Study selection and data extraction: All English-language observational studies assessing the association between azithromycin and QT prolongation or cardiovascular risk were evaluated. Case reports describing this potential association were also reviewed. Data synthesis: A total of 6 case reports have shown a possible association between azithromycin and QT prolongation. In 3 of these cases, proarrhythmic events were reported. In a prospective observational study of 47 individuals with low cardiovascular risk, electrocardiograms were compared before and after 5 days of azithromycin treatment. Mild prolongation of the QTc was noted, but it was statistically insignificant compared with baseline. No arrhythmias were observed. A large observational cohort study found a small increase in cardiovascular deaths after azithromycin therapy, primarily among patients with high baseline cardiovascular risk. Conversely, a second cohort study involving a population of young to middle-aged adults failed to find an association. Conclusions: An emerging body of evidence suggests that azithromycin therapy may prolong the QT interval and, in rare cases, precipitate the potentially fatal arrhythmia torsade de pointes. Patients with additional risk factors for QT prolongation appear to be at highest risk, including women, elderly individuals; those with existing or prior history of cardiovascular disease, QT interval prolongation, hypokalemia, hypomagnesium, or bradycardia; and those using concomitant drugs associated with QT prolongation. For patients without these additional risk factors, azithromycin appears to be relatively safe.Keywords
This publication has 11 references indexed in Scilit:
- Use of Azithromycin and Death from Cardiovascular CausesNew England Journal of Medicine, 2013
- Azithromycin and the Risk of Cardiovascular DeathNew England Journal of Medicine, 2012
- Clarithromycin-Induced Long QT Syndrome: A Case ReportCase Reports in Medicine, 2012
- Azithromycin‐Induced Torsade De PointesPacing and Clinical Electrophysiology, 2007
- Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factorsJournal of Interventional Cardiac Electrophysiology, 2007
- Polymorphic Ventricular Tachycardia with a Normal QT Interval Following AzithromycinPacing and Clinical Electrophysiology, 2005
- Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de PointesThe Journal of pharmacology and experimental therapeutics, 2002
- Cellular and Ionic Mechanisms Underlying Erythromycin-Induced Long QT Intervals and Torsade de PointesJournal of the American College of Cardiology, 1996
- An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)The American Journal of Cardiology, 1992
- The pharmacokinetics of azithromycin in human serum and tissuesJournal of Antimicrobial Chemotherapy, 1990